Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2019, , 836 - 846, 04.09.2019
https://doi.org/10.18621/eurj.572606

Öz

Kaynakça

  • [1] Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-45.
  • [2] Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004;4:1662-8.
  • [3] Kolonko A, Chudek J, Szotowska M, Kuczera P, Wiecek A. Cardiovascular risk factors and markers of atherosclerosis in stable kidney transplant recipients. Transplant Proc 2016;48:1543-50.
  • [4] Yilmaz MI, Sonmez A, Saglam M, Cayci T, Kilic S, Unal HU, et al. A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol 2015;10:471-9.
  • [5] Sharaf El Din UA, Salem MM, Abdulazim DO. Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol 2016;5:398-417.
  • [6] Ioannou K, Stel VS, Dounousi E, Jager KJ, Papagianni A, Pappas K, et al. Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: a longitudinal study. PLoS One 2015;10:e0138461.
  • [7] Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676-85.
  • [8] Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
  • [9] Yildiz A, Fazlioglu M, Ersoy A, Gullulu M, Gullulu S, Yurtkuran M. Arterial elasticity measurement in renal transplant recipients. Transplant Proc 2007;39:1455-7.
  • [10] Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
  • [11] Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-62.
  • [12] WHO. BMI classification 20.03.2018. Available from: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
  • [13] Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-8.
  • [14] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
  • [15] Joist H, Brennan DC, Coyne DW. Anemia in the kidney-transplant patient. Adv Chronic Kidney Dis 2006;13:4-10.
  • [16] Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-29.
  • [17] Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
  • [18] Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Eyileten T, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007;83:392-7.
  • [19] Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 2005;16:1494-500.
  • [20] Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 2003;3:1393-9.
  • [21] Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study. Nephrol Dial Transplant 2006;21:2144-51.
  • [22] Mark PB, Murphy K, Mohammed AS, Morris ST, Jardine AG. Endothelial dysfunction in renal transplant recipients. Transplant Proc 2005;37:3805-7.
  • [23] Mercanoglu F, Turkmen A, Kocaman O, Pinarbasi B, Dursun M, Selcukbiricik F, et al. Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transplant Proc 2004;36:1357-60.
  • [24] Passauer J, Büssemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation 2003;75:1907-10.
  • [25] Roos M, Heinemann FM, Lindemann M, Horn PA, Lutz J, Stock K, et al. Fetuin-A pretransplant serum levels, kidney allograft function and rejection episodes: a 3-year posttransplantation follow-up. Kidney Blood Press Res 2011;34:328-33.
  • [26] Marechal C, Schlieper G, Nguyen P, Kruger T, Coche E, Robert A, et al. Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol 2011;6:974-85.
  • [27] Cianciolo G, Capelli I, Angelini ML, Valentini C, Baraldi O, Scolari MP, et al. Importance of vascular calcification in kidney transplant recipients. Am J Nephrol 2014;39:418-26.
  • [28] Min JK, Lin FY, Gidseg DS, Weinsaft JW, Berman DS, Shaw LJ, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the "warranty period" for remaining normal? J Am Coll Cardiol 2010;55:1110-7.
  • [29] McCullough PA. Annual progression of coronary calcification in trials of preventive therapies. Arch Intern Med 2009;169:2064-70.
  • [30] Nickel T, Schlichting CL, Weis M. Drugs modulating endothelial function after transplantation. Transplantation 2006;82(1 Suppl):S41-6.
  • [31] Westenfeld R, Schlieper G, Woltje M, Gawlik A, Brandenburg V, Rutkowski P, et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. Nephrol Dial Transplant 2011;26:4115-23.
  • [32] Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-66.
  • [33] Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
  • [34] Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2:1241-8.
  • [35] Sumida Y, Nakayama M, Nagata M, Nakashita S, Suehiro T, Kaizu Y, et al. Carotid artery calcification and atherosclerosis at the initiation of hemodialysis in patients with end-stage renal disease. Clin Nephrol 2010;73:360-9.
  • [36] Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001;15:181-5.
  • [37] Goldfarb-Rumyantzev AS, Naiman N. Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant 2010;25:1039-47.
  • [38] Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008;44:323-7.
  • [39] Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-41.
  • [40] Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001;31:509-19.
  • [41] Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003;23:489-94.
  • [42] Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 2006;26:423-9.
  • [43] El-Shehaby AM, Zakaria A, El-Khatib M, Mostafa N. Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest 2010;70:575-82.
  • [44] van Summeren MJ, Hameleers JM, Schurgers LJ, Hoeks AP, Uiterwaal CS, Kruger T, et al. Circulating calcification inhibitors and vascular properties in children after renal transplantation. Pediatr Nephrol 2008;23:985-93.
  • [45] Kuzniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end-stage kidney disease. J Ren Nutr 2008;18:83-6.

The evaluation of the relationship between fetuin-A and traditional and non-traditional cardiovascular risk factors in kidney transplantation recipients

Yıl 2019, , 836 - 846, 04.09.2019
https://doi.org/10.18621/eurj.572606

Öz

Objectives:
Kidney transplantation recipients (KTRs) have higher cardiovascular
complications risk compared to the general population. Cardiovascular risk
factors (CVRF, Traditional and non-traditional) are widely studied to
understand the causes of increased cardiovascular disease (CVD) risk in KTRs.
Fetuin-A prevents from vascular calcification (VC) by inhibiting production and
collapsing of apatite crystals to the vascular wall. The relationship between fetuin-A
levels and CVRF in KTRs was investigated in this study.

Methods: Sixty-two KTRs with no prior
CVD history participated. Anthropometrical, laboratory (fetuin-A, inflammation
markers, antioxidants, lipid peroxidation products) and cardiological
(echocardiographic, pulse wave velocity) measurements were performed.
Participants were divided into two groups according to normal (≥ 0.5 g/L, n = 32,
NFA) and low (< 0.5 g/L, n = 30, LFA) fetuin-A levels according to manufacturer’s
reference range, and the results were compared.

Results: No significant difference was observed in demographic features, body mass index, systolic and diastolic blood pressures, left ventricle mass index, waist and hip circumferences, left ventricle hypertrophy and waist-hip ratios between the two groups (p > 0.05). The ratios of drug usage such as immunosuppressives, anti-hypertensives and statin were comparable between two groups. Parathormone levels were significantly higher in the NFA group (p = 0.015) and glomerular filtration
rate was calculated significantly higher in LFA group (
p = 007). The comparison of other CVRF reveals no significant
difference (
p > 0.05).







Conclusions: Although many CVRF improved in
KTRs, subclinical inflammation markers were still higher than the healthy
population. Identification and early recognition of CVRF in high-risk
individuals may contribute to the reduction of cardiovascular mortality. In our
study, we observed no significant relationship between fetuin-A levels and
CVRFs. 
We evaluated the
relationship between serum fetuin-A levels on cardiovascular risk factors by
its role in pathophysiology. 

Kaynakça

  • [1] Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-45.
  • [2] Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004;4:1662-8.
  • [3] Kolonko A, Chudek J, Szotowska M, Kuczera P, Wiecek A. Cardiovascular risk factors and markers of atherosclerosis in stable kidney transplant recipients. Transplant Proc 2016;48:1543-50.
  • [4] Yilmaz MI, Sonmez A, Saglam M, Cayci T, Kilic S, Unal HU, et al. A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol 2015;10:471-9.
  • [5] Sharaf El Din UA, Salem MM, Abdulazim DO. Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol 2016;5:398-417.
  • [6] Ioannou K, Stel VS, Dounousi E, Jager KJ, Papagianni A, Pappas K, et al. Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: a longitudinal study. PLoS One 2015;10:e0138461.
  • [7] Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676-85.
  • [8] Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
  • [9] Yildiz A, Fazlioglu M, Ersoy A, Gullulu M, Gullulu S, Yurtkuran M. Arterial elasticity measurement in renal transplant recipients. Transplant Proc 2007;39:1455-7.
  • [10] Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-33.
  • [11] Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-62.
  • [12] WHO. BMI classification 20.03.2018. Available from: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
  • [13] Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-8.
  • [14] Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
  • [15] Joist H, Brennan DC, Coyne DW. Anemia in the kidney-transplant patient. Adv Chronic Kidney Dis 2006;13:4-10.
  • [16] Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-29.
  • [17] Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
  • [18] Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Eyileten T, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007;83:392-7.
  • [19] Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 2005;16:1494-500.
  • [20] Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 2003;3:1393-9.
  • [21] Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Fetuin-A and kidney function in persons with coronary artery disease--data from the Heart and Soul Study. Nephrol Dial Transplant 2006;21:2144-51.
  • [22] Mark PB, Murphy K, Mohammed AS, Morris ST, Jardine AG. Endothelial dysfunction in renal transplant recipients. Transplant Proc 2005;37:3805-7.
  • [23] Mercanoglu F, Turkmen A, Kocaman O, Pinarbasi B, Dursun M, Selcukbiricik F, et al. Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transplant Proc 2004;36:1357-60.
  • [24] Passauer J, Büssemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation 2003;75:1907-10.
  • [25] Roos M, Heinemann FM, Lindemann M, Horn PA, Lutz J, Stock K, et al. Fetuin-A pretransplant serum levels, kidney allograft function and rejection episodes: a 3-year posttransplantation follow-up. Kidney Blood Press Res 2011;34:328-33.
  • [26] Marechal C, Schlieper G, Nguyen P, Kruger T, Coche E, Robert A, et al. Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol 2011;6:974-85.
  • [27] Cianciolo G, Capelli I, Angelini ML, Valentini C, Baraldi O, Scolari MP, et al. Importance of vascular calcification in kidney transplant recipients. Am J Nephrol 2014;39:418-26.
  • [28] Min JK, Lin FY, Gidseg DS, Weinsaft JW, Berman DS, Shaw LJ, et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the "warranty period" for remaining normal? J Am Coll Cardiol 2010;55:1110-7.
  • [29] McCullough PA. Annual progression of coronary calcification in trials of preventive therapies. Arch Intern Med 2009;169:2064-70.
  • [30] Nickel T, Schlichting CL, Weis M. Drugs modulating endothelial function after transplantation. Transplantation 2006;82(1 Suppl):S41-6.
  • [31] Westenfeld R, Schlieper G, Woltje M, Gawlik A, Brandenburg V, Rutkowski P, et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease. Nephrol Dial Transplant 2011;26:4115-23.
  • [32] Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-66.
  • [33] Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
  • [34] Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2:1241-8.
  • [35] Sumida Y, Nakayama M, Nagata M, Nakashita S, Suehiro T, Kaizu Y, et al. Carotid artery calcification and atherosclerosis at the initiation of hemodialysis in patients with end-stage renal disease. Clin Nephrol 2010;73:360-9.
  • [36] Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001;15:181-5.
  • [37] Goldfarb-Rumyantzev AS, Naiman N. Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant 2010;25:1039-47.
  • [38] Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008;44:323-7.
  • [39] Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-41.
  • [40] Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001;31:509-19.
  • [41] Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003;23:489-94.
  • [42] Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 2006;26:423-9.
  • [43] El-Shehaby AM, Zakaria A, El-Khatib M, Mostafa N. Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest 2010;70:575-82.
  • [44] van Summeren MJ, Hameleers JM, Schurgers LJ, Hoeks AP, Uiterwaal CS, Kruger T, et al. Circulating calcification inhibitors and vascular properties in children after renal transplantation. Pediatr Nephrol 2008;23:985-93.
  • [45] Kuzniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end-stage kidney disease. J Ren Nutr 2008;18:83-6.
Toplam 45 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Biyokimya ve Hücre Biyolojisi (Diğer), Kalp ve Damar Cerrahisi, Organ Nakli , Üroloji
Bölüm Original Article
Yazarlar

Nizameddin Koca 0000-0003-1457-4366

Alparslan Ersoy 0000-0002-0710-0923

Barış Şensoy Bu kişi benim 0000-0003-0066-9946

Emine Kırhan Bu kişi benim 0000-0003-1521-9366

Sümeyye Güllülü Bu kişi benim 0000-0003-2831-002X

Melahat Dirican Bu kişi benim 0000-0002-4956-5278

Emre Sarandöl 0000-0002-2593-7196

Yayımlanma Tarihi 4 Eylül 2019
Gönderilme Tarihi 31 Mayıs 2019
Kabul Tarihi 26 Haziran 2019
Yayımlandığı Sayı Yıl 2019

Kaynak Göster

AMA Koca N, Ersoy A, Şensoy B, Kırhan E, Güllülü S, Dirican M, Sarandöl E. The evaluation of the relationship between fetuin-A and traditional and non-traditional cardiovascular risk factors in kidney transplantation recipients. Eur Res J. Eylül 2019;5(5):836-846. doi:10.18621/eurj.572606

e-ISSN: 2149-3189 


The European Research Journal, hosted by Turkish JournalPark ACADEMIC, is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

by-nc-nd.png

2024